Today we’re joined by Patrick Andre, Chief Scientific Officer at Diagonal Therapeutics.

A trained vascular biologist, Patrick’s career spans groundbreaking work at Pfizer, Acceleron, Pliant Therapeutics, and earlier companies, where he focused on TGF-β superfamily signaling and receptor pathways that keep blood vessels healthy. Now at Diagonal, he’s leading a bold mission: developing clustering antibodies that correct the root cause of serious genetic vasculopathies, rather than just managing symptoms.

In this episode, Patrick walks us through his personal journey into science, the company’s DIAGONAL platform, and their lead program DIAG723, which recently received Orphan Drug Designation for the rare disease HHT, and is advancing toward the clinic. We also discuss Diagonal’s oversubscribed $125 million Series B financing that closed in January 2026, and what clustering antibodies could mean for patients with HHT, pulmonary arterial hypertension, and beyond.

• 01:33 Meet Patrick Andre
• 08:01 Diagonal’s mission
• 11:39 What are clustering antibodies
• 16:05 Receptor clustering benefits for HHT and PAH
• 20:24 Preclinical data on preventing and reversing HHT pathology
• 22:39 The impact of the $125 Million Series B financing round

Interested in being a sponsor of an episode of our podcast? Discover how you can get involved here! 

Stay updated by subscribing to our newsletter

To dive deeper into the topic: 

• Vaderis emerges from stealth to start HHT trial
• Pulmonary hypertension after Winrevair: where GSK’s $950M bet fits
• New treatment for pulmonary hypertension: what biotech holds in store?